Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicenter observational cohort

Anita Bálint, Mariann Rutka, Martin Kolar, Martin Bortlik, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malickova, Milan Lukas, Zoltán Szepes, Ferenc Nagy, K. Palatka, Szilvia Lovas, Zsuzsanna Végh, Zsuzsanna Kürti, Ágnes Csontos, P. Miheller, T. Nyári, Renáta BorÁgnes Milassin, Anna Fábián, Kata Szántó, Péter L. Lakatos, T. Molnár, Klaudia Farkas

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therapy in maintaining mucosal healing in UC. Methods: CT-P13 trough levels, antibody positivity, serum inflammatory markers as CRP level, fecal calprotectin at weeks 14 and 54, concomitant steroid and azathioprine therapy at the time of induction therapy and at weeks 14 and 54, previous use of anti TNF drug and the need of dose intensification as possible predictive factors for mucosal healing at week 54 were evaluated in this prospective study. Results: 61 patients had already completed the 54-week treatment period. Mucosal healing was shown in 65.5 % and 62.1 %, complete mucosal healing was present in 31% and 38 % at week 14 and 54, respectively. The median values of CRP, leukocytes, thrombocytes, and albumin showed significant difference between baseline and week 54. Serum antibody positivity was proved in 6.5 % and 19.7 % of cases at week 14 and 54, respectively. Conclusion: Our study confirmed the long-term efficacy of CT-P13 therapy on mucosal healing in UC.

Original languageEnglish
Pages (from-to)1181-1187
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2 2018

Keywords

  • CT-P13
  • Ulcerative colitis
  • infliximab biosimilar
  • long-term efficacy
  • mucosal healing

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicenter observational cohort'. Together they form a unique fingerprint.

  • Cite this

    Bálint, A., Rutka, M., Kolar, M., Bortlik, M., Duricova, D., Hruba, V., Lukas, M., Mitrova, K., Malickova, K., Lukas, M., Szepes, Z., Nagy, F., Palatka, K., Lovas, S., Végh, Z., Kürti, Z., Csontos, Á., Miheller, P., Nyári, T., ... Farkas, K. (2018). Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicenter observational cohort. Expert Opinion on Biological Therapy, 18(11), 1181-1187. https://doi.org/10.1080/14712598.2018.1530758